Emma Reeve Purchases Whitehawk Therapeutics Shares
On June 12, 2026, Emma Reeve bought 38,040 shares of Whitehawk Therapeutics, Inc.
Key Points
- Emma Reeve acquired 38,040 shares of Whitehawk Therapeutics on June 12, 2026, as part of insider trading activity.
- Whitehawk Therapeutics, Inc. (NasdaqCM: WHWK) trades at $4.16 with a market cap of $202.8 million and a 52-week range of $1.57 to $5.50.
- Analysts from Citizens and Jones Trading have set 'buy' ratings for Whitehawk Therapeutics with price targets of $8.00 and $7.00, respectively.
On June 12, 2026, Emma Reeve bought 38,040 shares of Whitehawk Therapeutics, Inc. (NasdaqCM: WHWK). This insider transaction did not specify a purchase price or total value, but it adds to the company's insider activity.
Insider Buying and Selling at Whitehawk Therapeutics, Inc.
Several insiders, including Emma Reeve, participated in buying shares on June 12, 2026. Each insider, including Castelein Caley, Desai Neil, Maroun Richard, Zhao Baiteng, and Aghazadeh Behzad, acquired 38,040 shares. These transactions were not part of any pre-planned trading program.
Other Institutional Activity in Whitehawk Therapeutics
In recent institutional activity, QVT Financial LP holds 4,615,709 shares worth approximately $15.9 million. Orbimed Advisors LLC has 4,166,000 shares valued at about $14.4 million. Suvretta Capital Management, LLC maintains 3,700,000 shares, with a value of $12.8 million. Acuta Capital Partners, LLC possesses 3,410,402 shares, valued at roughly $11.8 million. Finally, Avoro Capital Advisors LLC holds 2,849,402 shares worth $9.8 million.
Whitehawk Therapeutics Stock Snapshot
Shares of Whitehawk Therapeutics, Inc. (NasdaqCM: WHWK) are trading at $4.16. The company has a market capitalization of $202.8 million. It has a beta of 0.769, indicating less volatility compared to the overall market. The stock's 52-week range spans from $1.57 to $5.50. Its 50-day moving average is $4.15, and the 200-day moving average is $2.98. The company has a strong current ratio of 11.36, reflecting its liquidity position.
Analysts Set New Price Targets
On April 16, 2026, Citizens initiated coverage of Whitehawk Therapeutics with a 'buy' rating and an $8.00 price target. Previously, on December 22, 2025, Jones Trading also initiated coverage with a 'buy' rating and a $7.00 price target. The consensus among four analysts suggests a 'buy' recommendation, with an average price target of $6.50.
About Whitehawk Therapeutics
Whitehawk Therapeutics, Inc. is a clinical-stage company in the biotechnology industry, focusing on oncology therapeutics. Headquartered in Morristown, New Jersey, the company develops technologies to understand tumor biology for cancer treatments. It offers a portfolio of next-generation antibody drug conjugates aimed at treating cancer. Dr. David J. Lennon, Ph.D., leads the company as CEO, and it employs 29 people.
Bottom Line
Emma Reeve's recent purchase of Whitehawk Therapeutics shares highlights ongoing insider interest in the company. With a market cap of $202.8 million and trading at $4.16, investors might find the company's strategic focus on cancer treatments noteworthy. It's important to remember that insider transactions like these are disclosed after the fact and may not indicate future performance.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.